Abstract
Due to patient heterogeneity, the exact mechanisms of paediatric abdominal pain (AP) remain unknown. We sought to resolve this by identifying paediatric AP phenotypes and developing predictive models to determine their associated factors. In 13,790 children from a large birth cohort, the frequencies of paediatric and maternal demographics and comorbidities were catalogued from general practitioner records. Unsupervised machine learning clustering was used to identify phenotypes of paediatric AP with shared characteristics. Predictive paediatric AP models were constructed using paediatric and maternal demographics and comorbidities.
1,274 children experienced AP (9.2 %) (average age: 8.4 ± 1.1 years old, male/female: 615/659), who clustered into 3 distinct phenotypes: phenotype 1 with an allergic predisposition (n = 137), phenotype 2 with maternal comorbidities (n = 676), and phenotype 3 with minimal other comorbidities (n = 340). As the number of allergic diseases or maternal comorbidities increased, so did the frequency of AP, with 17.6% of children with ≥ 3 allergic diseases and 25.6% of children with ≥ 3 maternal comorbidities. Furthermore, in high-risk children who met both ≥ 3 allergic diseases and ≥ 3 maternal comorbidities, 30.8% had AP. Predictive models demonstrated modest fidelity in predicting paediatric AP (AUC 0.66), showing that a child’s ethnicity and paediatric/maternal comorbidities were strongly predictive factors. Our findings reveal distinct phenotypes and associated factors of paediatric AP, suggesting targets for future research to elucidate the exact mechanisms of paediatric AP related to allergic diseases, ethnicity, and maternal comorbidities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by JA Niigata Kouseiren Grant (Niigata University School of Medicine).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used human data that are available with permission.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
H.Satti and Q.Aziz are joint senior authors.
Due to issues with the genetic analysis method, we have excluded the results of the genetic analysis in this version.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.